Baxter International Inc. · NYSE:BAX
Baxter International — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
14 slides from Baxter International's conference presentation, Jan 8, 2024
Slide 1: 42nd Annual J.P. Morgan Healthcare Conference
42 ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE José (Joe) Almeida Chairman & Chief Executive Officer JANUARY 8, 2024 1
Slide 2: Safe Harbor Statement
S A F E H A R B O R S TAT E M E N T This presentation includes forward-looking statements concerning the company’s financial results , 2022 – 2025 market growth rates, business development and regulatory activities and the company’s ongoing strategic actions. These forward-looking statements are bas
Slide 3: Steadfast to our mission of saving and sustaining lives
S T E A D FA S T T O O U R MISSION OF S AV I N G A N D S U S TA I N I N G L I V E S 3
Slide 4: Global, diversified and market leading portfolio
GLOBAL, DIVERSIFIED AND MARKET LEADING PORTFOLIO 350+ Million Patients’ lives touched annually Medical Products & Therapies Healthcare Systems & Technologies 100+ Countries served by Baxter products Pharmaceuticals Kidney Care Information on this slide as of December 31, 2023. 4
Slide 5: 2030 Corporate Responsibility Commitments
2 0 3 0 C O R P O R AT E R E S P O N S I B I L I T Y C O M M I T M E N T 1 > Achieve carbon neutrality for > Bring home dialysis to more > Invest $275 million in direct operations by 2040 underserved patients underserved communities > Reduce greenhouse gas > Improve product process > Achieve top wor
Slide 6: Baxter continues to meet patient and provider needs in durable established markets
B A X T E R C O N T I N U E S T O M E E T PAT I E N T A N D P R O V I D E R N E E D S I N D U R A B L E E S TA B L I S H E D M A R K E T S YTD ’23 Sales 1 Current Portfolio2 ’23 – ’26 3%+ Infusion IV Hemostats Cernevit Microsurgery Systems Therapies & Sealants expected market Medical Products growth
Slide 7: Baxter on track to deliver differentiated product innovations
B A X T E R O N T R A C K T O D E L I V E R D I F F E R E N T I AT E D P R O D U C T I N N O VAT I O N S 1 Near Term Launches2 Future Launches Novum IQ LVP & Syringe Infusion Platform (Canada / U.S.) Ambulatory Pump EMR Connectivity, Over the Air Software Upgrades, and Asset Tracking Hospital & alte
Slide 8: Kidney Care includes market-leading portfolio within essential renal segments
KIDNEY CARE INCLUDES MARKET-LEADING PORTFOLIO WITHIN ESSENTIAL RENAL SEGMENTS YTD ’23 Sales1 Current Portfolio2 Ecosystem ’23 – ’26 3-4% expected market growth rate4 PD Cyclers & Solutions MyPD Patient App Analytics and Decision Support Anticipated market growth Chronic Therapies3 $2.7B driven by: •
Slide 9: KidneyCo being structured to continue to drive patient-focused innovation with strong R&D pipeline
K I D N E YC O B E I N G S T R U C T U R E D T O C O N T I N U E T O D R I V E PAT I E N T - F O C U S E D I N N O VAT I O N W I T H S T R O N G R & D P I P E L I N E 1 Near Term Launches2 Future Launches Sharesource Analytics Home PD Solution Generation Data visualization to help clinicians Leverag
Slide 10: Progress update on strategic actions to deliver enhanced shareholder value
P R O G R E S S U P D AT E O N S T R AT E G I C A C T I O N S TA K E N T O D E L I V E R E N H A N C E D S H A R E H O L D E R VA L U E Complete Complete In Progress • Finalized operating model • Completed the divestiture • Continuing to progress on and in Q3 2023 began of the BioPharma Solutions th
Slide 11: Enhancing Baxter's value creation potential through portfolio actions and simplified operating model
E N H A N C I N G B A X T E R ’ S VA L U E C R E AT I O N P O T E N T I A L T H R O U G H P O R T F O L I O A C T I O N S A N D S I M P L I F I E D O P E R AT I N G M O D E L • Streamline portfolio and commercial structure to fulfill Baxter’s vision • Accelerate commercial investments to further pen
Slide 12: Kidney Care separation expected to accelerate value creation potential
K I D N E Y C A R E S E PA R AT I O N E X P E C T E D T O A C C E L E R AT E VA L U E C R E AT I O N P O T E N T I A L • Increase PD and HDx therapy penetration in existing geographies • Drive CRRT portfolio expansion in the U.S. and Commercial geographic expansion in emerging markets Enhance value
Slide 13: Continuing momentum in 2024 and beyond
C O N T I N U I N G M O M E N T U M I N 2 0 24 A N D B E YO N D Building on underlying 2023 business momentum and financial progress Actively progressing on proposed separation of Kidney Care to create two leading healthcare companies with robust product portfolios Separation expected to enhance val
Slide 14: 42nd Annual J.P. Morgan Healthcare Conference
42 ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE José (Joe) Almeida Chairman & Chief Executive Officer JANUARY 8, 2024 14
Baxter International — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix